PRO#0118: Decitabine Plus Mini Flu-Bu

Completed · Phase 1

Conditions studied: Acute Myeloid Leukemia, Myelodysplastic Syndrome

In brief

This is a single institution study of combining decitabine with fludarabine and busulfan in the setting of allogeneic stem cell transplantation. A study population of 20 subjects will be enrolled from The John Theurer Cancer Center at Hackensack University Medical Center. Subjects who are eligible to receive allogeneic hematopoietic stem cell transplantation according to the eligibility criteria will be consented and enrolled. Subjects will receive treatment with decitabine followed by reduced intensity fludarabine and busulfan prior to allogeneic stem cell transplantation. Subjects will be followed until 1 year post transplantation to assess stability of engraftment, toxicity, progression free survival, and disease response

Key facts

Study ID
NCT01455506
Run by
Hackensack Meridian Health
People needed
20
Starts
2009-05-01
Expected to finish
2013-12-01
Last updated by the study team
2014-02-04

Who can join

Age: 45 and older, up to 80. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.